Denali Therapeutics
DNLI
209 hedge funds and large institutions have $2.47B invested in Denali Therapeutics in 2023 Q4 according to their latest regulatory filings, with 37 funds opening new positions, 71 increasing their positions, 69 reducing their positions, and 20 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 3 → 6 (+3)
85% more first-time investments, than exits
New positions opened: 37 | Existing positions closed: 20
23% more call options, than puts
Call options by funds: $1.82M | Put options by funds: $1.48M
10% more capital invested
Capital invested by funds: $2.24B → $2.47B (+$225M)
8% more funds holding
Funds holding: 194 → 209 (+15)
4.29% more ownership
Funds ownership: 79.06% → 83.34% (+4.3%)
3% more repeat investments, than reductions
Existing positions increased: 71 | Existing positions reduced: 69
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marshall Wace
London,
United Kingdom
|
+$33M |
| 2 |
State Street
Boston,
Massachusetts
|
+$24M |
| 3 |
BlackRock
New York
|
+$13M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
+$12.8M |
| 5 |
B
Braidwell
Stamford,
Connecticut
|
+$9.15M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WP
Woodline Partners
San Francisco,
California
|
-$13M |
| 2 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$12.8M |
| 3 |
DM
Deerfield Management
New York
|
-$12.3M |
| 4 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
-$11M |
| 5 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
-$8.32M |
DNLI Hedge Fund Activity: Q4 2023 in Review
209 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in Denali Therapeutics (DNLI) for Q4 2023, worth a combined $2.47B — up 10% from $2.24B a quarter earlier.
Buyers outnumbered sellers: 37 funds opened new DNLI positions and 20 closed out — a net gain of 17 holders — while 71 added to existing stakes and 69 trimmed.
The largest buyer was Marshall Wace, opening a new position worth an estimated $33M. The largest seller was Woodline Partners, cutting an estimated $13M.
- 209 institutional investors held Denali Therapeutics (DNLI) as of Q4 2023, up from 194 in Q3 2023.
- Funds reported $2.47B of Denali Therapeutics stock for Q4 2023, up 10% quarter-over-quarter.
- 37 funds opened new Denali Therapeutics positions in Q4 2023 and 20 closed out, a net change of +17 holders.
- The largest Denali Therapeutics buyer in Q4 2023 was Marshall Wace, an estimated $33M added.
- The largest Denali Therapeutics seller in Q4 2023 was Woodline Partners, an estimated $13M sold.
Based on aggregated 13F filings for Q4 2023.